Manager TitleAgeSince
Chief Executive Officer 52 2024-12-15
Director of Finance/CFO 56 2022-12-31
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Chairman 69 2011-12-31
Director/Board Member 56 2019-12-31
Director/Board Member 54 2020-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-44.44%-44.44% - - 97.91K
-0.53%-3.95%+50.70%+153.56% 1,024B
+0.21%-2.68%+53.20%+51.79% 618B
-2.51%-3.25%+28.54%+68.94% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.69%-0.30%+13.76%+12.83% 264B
-7.37%-4.40%-0.74%-44.28% 209B
-0.64%+2.43%+29.74%+65.93% 208B
-0.82%+0.70%+15.05%+72.05% 162B
+0.40%+1.92%+6.47%-29.77% 143B
Average -5.63%-1.21%+26.03%+42.41% 379.88B
Weighted average by Cap. -1.00%-2.02%+36.14%+71.90%
Logo Lipigon Pharmaceuticals AB
Lipigon Pharmaceuticals AB is a Sweden-based project portfolio company. Lipigon's business concept is to develop medicines with new, unique mechanisms of action (so-called first-in-class) for diseases that lack adequate treatment. The Company develops medicines with a focus on diseases where the body's ability to handle fats is disturbed, so-called lipid-related diseases, and where there are unmet medical needs. Initially, the Company's development focuses on advanced diseases or genetically defined patient segments where it is possible to identify treatment effects early in the clinical development. It creates the conditions for studies with fewer patients and a shorter path to market approval and thus a reduced development risk.
Employees
5
  1. Stock Market
  2. Stocks
  3. LPGO Stock